Company news: Bod Science; Emyria by Martin Lane November 21, 2023April 30, 2024 Bod Science has yet to settle tranche one of its current capital raise following delays in […]
Bod announces A$2m capital raise as senior team takes pay cut by Martin Lane November 8, 2023April 30, 2024
Bod Science plots another capital raise as expanded product range set to launch by Steve Jones October 31, 2023April 30, 2024
TGA to stick with 150mg dose of CBD amid Cann Group ‘surprise’ at UK advice by Steve Jones October 25, 2023April 30, 2024
Bod eyes opportunities beyond cannabis as Aqua Phase tech passes second bioavailability test by Martin Lane September 27, 2023April 30, 2024
Long-time cannabis critic says medicine’s growth ‘more concerning’ than opioid epidemic by Martin Lane September 18, 2023September 20, 2023
Bod Science clinical trial ‘proves the efficacy of CBD’ for pharmacy sales by Steve Jones September 6, 2023September 7, 2023
Bod Science eyes new revenue streams after reporting heavy loss by Steve Jones August 30, 2023August 30, 2023